I have spent the last decade in the trenches of biotech business development. I’ve seen companies blow half their annual travel budget on a suite at the St. Regis for JPM Week, only to spend the entire week in meetings that lead to nothing. I’ve watched teams walk into events hosted by Demy-Colton or Informa Connect without a clear target list, treating a badge scan like a golden ticket. It isn't.
If you want to move the needle on capital formation or licensing, you need to stop "networking" and start executing a logistical operation. This is your reality check on conference ROI and opportunity cost.
The ROI Reality Check: Opportunity Cost is Your Real Budget
Most biotech leaders measure conference success by the number of business cards collected or the number of coffee meetings they managed to cram into a four-day window. This is a vanity metric. Your real budget isn't the conference registration fee or the flight to San Francisco; it is the 96 hours your entire senior leadership team is effectively off-site. If you aren't booking high-quality 1:1s, that time is an expensive loss.
Before you commit to a major show, calculate the opportunity cost. If you are a genomics startup, are you chasing generalists who don't understand your multiomics platform, or are you sitting down with specialized corporate VCs (CVCs)? A meeting that doesn't advance a term sheet or a due diligence conversation is a waste of your time. Full stop.
The "Avoid" List: Where Companies Waste Time
Not every event is worth the footprint. Here is my current "do not bother" list for companies looking for serious partnering:
- The "Open Networking" Cocktail Hour: Unless you are a master of high-pressure social engineering, you won't find a partner here. You’ll find people looking for free drinks. Broad-spectrum Panel Discussions: If your team is sitting in the audience while they should be in 1:1s, you are losing money. Events in "Far-Flung" Neighborhoods: During JPM Week, if your meeting is in a hotel that requires a 20-minute Uber in San Francisco traffic, you’ve lost a meeting slot. Stay in the cluster.
The Data Layer: Tech Friction and Lead Capture
If your partnering strategy relies on your website or a portal, you need to ensure the tech isn't blocking your own success. I’ve seen teams lose out on critical partner follow-ups because their own site's security settings blocked the connection. If you are using sophisticated tools to gate your content or manage traffic, ensure your tracking isn't over-blocking.
For example, if you are running custom landing pages for investors, ensure that your CookieYes consent banner isn't obscuring the "Book a Meeting" call-to-action on mobile devices. Furthermore, if you’re using Cloudflare Bot Management to keep your site lean, double-check that your legitimate partners aren't getting flagged. If a lead’s browser returns a 403 because your __cf_bm or _cfruid cookies are misconfigured, you’ve just effectively told a potential partner to go away.
When you are in the partneringONE system, your "About Us" blurb needs to be punchy. Don’t use buzzwords like "synergistic paradigm shift." Use data. If you’re a multiomics firm, state the specific assay throughput and the validation stage. The partnering portal is a search engine; act like an SEO expert, not a marketer.
biotech investor conference San FranciscoBuilding Your Target List: A Functional Breakdown
Your partnering prep checklist should start with a segmented target list. Do not aim for "everyone." Use the following table to organize your approach:
https://dlf-ne.org/surviving-and-thriving-your-strategy-for-san-diego-conference-week-2026/ Segment Primary Objective Key Talking Point Pharma BD Leads Licensing/M&A Pipeline fit and unmet medical need. Specialist Investors Capital Formation Milestone-based value inflection. Tech Collaborators Multiomics/Platform Validation Data interoperability and scalability.Build this list 60 days out. Assign every target to a team member. If a person is assigned to "Pharma BD," they should not be handling the generalist investors. Different targets require different levels of pitch meeting readiness.
The Geography of Flow: Why Neighborhoods Matter
I am obsessed with venue flow because I have spent too many JPM weeks sprinting from the Union Square hotels to the SoMa district, only to be late for a critical meeting.
When scheduling, map your meetings by geography. If you are at a conference in Boston, don't schedule a breakfast in the Seaport and a 9:00 AM in Kendall Square. You will fail. During these intense partnering weeks, your biggest enemy is transit. Block out "transit time" in your internal calendar and stick to it. If you can, centralize your meetings in one "home base" hotel lobby or suite. If you have to move, stay within a five-minute walking radius.
Pitch Meeting Readiness: Genomics and Multiomics Focus
The trend in multiomics right now is integration. Investors are bored of "we do sequencing." They want to see how you integrate proteomics with transcriptomics and—more importantly—what your clinical endpoint strategy is. Your pitch should be a three-act structure:
The Biological Insight: Why your target is clinically relevant. The Data Proof: How your tech provides a higher signal-to-noise ratio than the current standard. The Commercial Path: Not just "we have a platform," but "we have a pipeline of assets in X stage."Do not go into a pitch with a 40-page slide deck. Have a "leave-behind" one-pager that is strictly data-focused. Investors get 50 decks a day; they will only remember the one that has a clean, defensible table of your current data versus the market standard.
The Post-Conference Trap
The most common failure point isn't the meeting—it’s the two weeks *after* the conference. I see teams return from JPM or a BIO-hosted event and let the momentum die because they are overwhelmed with follow-ups.
Before you leave for the conference, have your CRM (Salesforce, HubSpot, or even a simple Airtable) pre-configured with a "Post-Conference" workflow. If you aren't sending personalized follow-ups within 48 hours, you have wasted the 1:1 meeting time. And for heaven’s sake, stop sending the generic "Great meeting, let’s stay in touch" email. Reference a specific data point you discussed or a question they asked about your multiomics platform.
Summary: Your Execution Checklist
If you take nothing else away from this, follow this final checklist before your next major event:
- Audit your digital presence: Ensure your partner portal profile and website are functioning and not blocking incoming traffic through aggressive bot management. Build a tiered target list: Categorize your partners into BD, Investor, and Strategic Collaborator. Map your geography: Keep meetings within a tight, walkable radius to maximize volume and reduce stress. Refine your pitch: Cut the buzzwords. If you are a genomics company, show me the data, not the vision board. Automate your follow-up: Have your CRM ready to trigger personalized follow-ups before you even land in the host city.
Stop trying to "network" and start building a pipeline. Partnering isn't a social event; it’s a high-stakes business transaction. Treat it like one, and you’ll find your time in the trenches actually pays off.